EUVIMEDEUVIMED entdecken
Crossref

Management of homologous recombination deficient (HRD) epithelial ovarian cancer

Σωτήριος Α. Παπαβασιλείου

Aristotle University of Thessaloniki · 01.01.2026

DOI: 10.26262/heal.auth.ir.376474 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Aristotle University of Thessaloniki, erschienen am 01.01.2026. Verfasst von Σωτήριος Α. Παπαβασιλείου.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ovarian cancer represents a significant public health challenge today, contributing substantially to cancer-related morbidity and mortality worldwide. The present thesis explores contemporary strategies for treating HRD ovarian cancer, a condition characterized by defective DNA repair mechanisms, particularly in the homologous recombination pathway. The study provides a comprehensive review of the epidemiology, risk factors, molecular pathology, staging, and biomarkers of ovarian cancer, with a focus on HRD-positive cases. The review highlights the role of Poly-ADP Ribose Polymerase inhibitors (PARPi) as a pivotal advancement in the therapeutic landscape. These agents exploit synthetic lethality by targeting tumor cells deficient in homologous recombination repair, particularly those with BRCA1/2 mutations. Key clinical trials such as SOLO-1, PRIMA, and PAOLA-1 demonstrate the efficacy of PARPi in both newly diagnosed and recurrent settings. Maintenance therapies using PARPi have shown significant improvements in progression-free survival, particularly in patients with BRCA mutations or HRD-positive tumors. The thesis also evaluates combination therapies, including PARPi with immune checkpoint inhibitors and antiangiogenic agents, revealing potential synergistic effects. Additionally, it discusses the challenges of resistance development, adverse effects, and the need for HRD testing to optimize patient selection. Concluding, the study underscores the importance of personalized medicine and genetic testing in advancing treatment outcomes for HRD epithelial ovarian cancer. It recommends further research into biomarkers and combination strategies to overcome resistance and improve overall survival.

Schlagwörter

homologous recombination deficiencyepithelial ovarian cancerPARP inhibitorssynthetic lethalityBRCA mutationsmaintenance therapyimmune checkpoint inhibitorsangiogenesis inhibitorsPARP inhibitor resistanceHRD testing

Zitieren

APA

Παπαβασιλείου, Σ. Α. (2026). Management of homologous recombination deficient (HRD) epithelial ovarian cancer. Aristotle University of Thessaloniki. https://doi.org/10.26262/heal.auth.ir.376474

Vancouver

Παπαβασιλείου ΣΑ. Management of homologous recombination deficient (HRD) epithelial ovarian cancer. Aristotle University of Thessaloniki. 2026. doi:10.26262/heal.auth.ir.376474

BibTeX
@article{2026,
  author = {Παπαβασιλείου, Σωτήριος Α.},
  title = {Management of homologous recombination deficient (HRD) epithelial ovarian cancer},
  journal = {Aristotle University of Thessaloniki},
  year = {2026},
  doi = {10.26262/heal.auth.ir.376474}
}
Kostenlos starten →